Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET: TEG-PM-Guided Antiplatelet Therapy in PAD
NCT07597239Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2023
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial in peripheral artery disease (PAD), sponsored by Massachusetts General Hospital. Primary endpoint: Target-Vessel Thrombosis or Clinically Significant Stenosis at 12 months. Started Jan 2023; status: active, not recruiting.
02
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT07597239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07597239.